Navigation Links
International team analyzes human genetic variation in key immune region

An international group of researchers today unveiled a detailed map of human genetic variation within the major histocompatibility complex (MHC), the most important region of the human genome encoding the human response to infection, autoimmune disease and organ transplantation. The work represents a milestone in the analysis of genetic variability for this fundamental immune region and lays the scientific foundation for future efforts aimed at uncovering the genetic roots of immune-related diseases. The findings of this international team, which includes scientists from the Montreal Heart Institute (MHI), the Université de Montréal (UdeM), the Broad Institute of MIT and Harvard and several other research institutions, appear in the September 24 advance online edition of Nature Genetics.

"This new map will be a key resource for researchers to use to find genes affecting health, disease, and responses to medications," said senior author Dr. John D. Rioux, PhD, who is associate professor of medicine at the UdeM and at the MHI where he works as a researcher and director of the Laboratory in Genetics and Genomic Medicine of Inflammation (www.inflammgen.org), visiting scientist of the Broad Institute of MIT and Harvard, and holder of the Canada Research Chair in Genetics and Genomic Medicine of Inflammation. "It will provide the information necessary to design powerful studies to identify the genetic risk factors located within the MHC."

The MHC -- specifically, the genes that comprise it -- is associated with more diseases than any other region of the human genome. This includes common diseases such as atherosclerosis, arthritis, diabetes, HIV, lupus, multiple sclerosis and Crohn's disease. However, pinpointing the specific changes that are causative in these diseases has been complicated by two factors: the extremely high degree of genetic diversity that exists in the MHC among different individuals and the tend
'"/>

Source:University of Montreal


Page: 1 2 3

Related biology news :

1. International trial of two microbicides begins
2. International HapMap consortium expands mapping effort
3. Solutions that reduce death of marine life reeled in by International Smart Gear Competition
4. International Team Determines Geographic Origin of Leprosy
5. International HIV/AIDS trial finds continuous antiretroviral therapy superior to episodic therapy
6. Novel technology detects human DNA mutations
7. Current human embryonic stem cell lines contaminated UCSD/Salk team finds
8. UWs Rosetta software to unlock secrets of many human proteins
9. Genome-wide mouse study yields link to human leukemia
10. Found: Missing sequence of the human Y chromosome
11. Study finds more than one-third of human genome regulated by RNA
Post Your Comments:
(Date:7/25/2014)... time, Spanish researchers have detected an unknown interaction between ... are introduced into a droplet of salt water and ... crystallisation to create biomineralogical biosaline 3D morphologically complex formations, ... bacteria are revived. The discovery was made by chance ... of the Astrobiology journal and may help ...
(Date:7/24/2014)... -- The Geneva Healthcare Suite, an innovative technology platform ... room wait times by an average of 92 minutes ... to a recent study published in the Academic Emergency ... suite to access data from incoming patients, implanted cardiac ... Geneva,s technology platform we have been able to quickly ...
(Date:7/24/2014)... A new study has identified two factors that ... increase the production of highly qualified physics teachers. ... to champion physics teacher education in combination with ... initiatives remain viable. Science, Technology, Engineering and Math ... and the study points the way for institutions ...
Breaking Biology News(10 mins):Bacteria manipulate salt to build shelters to hibernate 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 3Creating sustainable STEM teacher preparation programs 2
... Department of Cell Biology and Histology at the University of ... boosted by means of retinoids. It was thought that this ... , Vitamin A, also known as retinol, is ... and as carotene in vegetables that have a yellow-orange colour, ...
... identified a compound that interferes with the pathogenic effects ... development of a new treatment for the disease. , ... that now afflicts 30,000 Americans, with another 150,000 at ... strikes in midlife and causes uncontrolled movements, loss of ...
... Dentistry professor has developed a calcium phosphate-based supplement that ... strength and thickness without the side effects of many ... of Biomaterials and Biomimetics and of Implant Dentistry, presented ... for Dental Research annual meeting on March 9, 2006. ...
Cached Biology News:Retinol for combating leukemia cells 2Retinol for combating leukemia cells 3MIT research holds promise for Huntington's treatment 2New study reveals promising osteoporosis treatment 2
(Date:7/25/2014)... Amgen (NASDAQ: AMGN ) announced ... per share dividend for the third quarter of 2014. ... to all stockholders of record as of the close ... About Amgen Amgen is committed to unlocking the potential ... discovering, developing, manufacturing and delivering innovative human therapeutics. This ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 According to ... "Biological Drugs Market - Global Industry Analysis, Size, Share, ... biological drugs market is estimated at USD 161,056.5 million ... CAGR of 10.1% from 2014 to 2020, to reach ... , The biological drugs market is witnessing a significant ...
(Date:7/25/2014)...  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ) ... and commercialization of a once-daily, oral therapy for the ... financial results for the period ended June 30, 2014. ... Reported cash and cash equivalents totaling $37.4 million on ... 2013.  , Reported a net loss of $3.9 ...
(Date:7/24/2014)... 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced ... control Phase 3 study of Zerenex (ferric citrate), the ... treatment of hyperphosphatemia in patients with end-stage renal disease ... iRon delivery with FErric CiTrate in EsrD) was published ... Society of Nephrology ( JASN ). ...
Breaking Biology Technology:Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4
... Microdosing or Phase 0 clinical testing has ... phase of the drug development process in the ... providers in preclinical testing and technology dependence is ... alliances, fuelling growth opportunities in this sector.(Logo: ...
... BASEL, Switzerland, Feb. 10 Syngenta today announced that ... Rice Research Institute (ARRI) of Anhui Academy of Agricultural ... conducting laboratory and field tests of novel gene functions ... optimization in key crops such as corn and soybean. ...
... CHAMPAIGN, Ill. By pushing carbon nanotubes close ... of Illinois have demonstrated a remarkable increase in ... what was previously thought possible., The researchers drove ... carries more electrons down more paths, similar to ...
Cached Biology Technology:Frost & Sullivan Sees Microdosing as Compelling Advantage for Big Pharma 2Frost & Sullivan Sees Microdosing as Compelling Advantage for Big Pharma 3Syngenta Enters Into Research Collaboration With Anhui Academy, China 2Syngenta Enters Into Research Collaboration With Anhui Academy, China 3Carbon nanotube avalanche process nearly doubles current 2
Abgene's ALTO-8 is the first automated decapper/capper for Abgene Twist-Lock tubes....
... is an enhanced form of Tobacco Etch ... highly active, and significantly more stable than ... AcTEV Protease specifically recognizes a seven amino ... making it useful for removing affinity tags ...
... The Heraeus HERAcell is the ideal ... including development of ova or embryos at ... specifically designed to provide everything needed to ... , , Safe and stable incubation conditions ...
SP6 RNA Polymerase, 50 l, 20 U/l ,Cap Scribe Buffer, 100 l, 5x conc....
Biology Products: